– Phase 1 trial of SEL-302 remains on track to initiate in the second half of 2022 –
– DISSOLVE I & II studies on track for completion in Q4 2022 with joint topline readout in Q1 2023 –
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
– Phase 1 trial of SEL-302 remains on track to initiate in the second half of 2022 –
– DISSOLVE I & II studies on track for completion in Q4 2022 with joint topline readout in Q1 2023 –
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| SELB | 0.8812 | -0.0766 | -8.00% |
| Selecta Biosciences | |||